New York State Common Retirement Fund Purchases 3,820 Shares of IDEXX Laboratories, Inc. $IDXX

New York State Common Retirement Fund raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.8% in the third quarter, HoldingsChannel.com reports. The fund owned 60,225 shares of the company’s stock after purchasing an additional 3,820 shares during the quarter. New York State Common Retirement Fund’s holdings in IDEXX Laboratories were worth $38,477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the company. Empowered Funds LLC lifted its stake in IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in IDEXX Laboratories during the second quarter worth approximately $265,000. Institute for Wealth Management LLC. bought a new stake in IDEXX Laboratories in the second quarter valued at approximately $219,000. Robeco Institutional Asset Management B.V. lifted its position in shares of IDEXX Laboratories by 39.8% in the second quarter. Robeco Institutional Asset Management B.V. now owns 207,228 shares of the company’s stock valued at $111,145,000 after buying an additional 58,991 shares during the last quarter. Finally, J. Safra Sarasin Holding AG lifted its position in shares of IDEXX Laboratories by 74.2% in the second quarter. J. Safra Sarasin Holding AG now owns 3,610 shares of the company’s stock valued at $1,936,000 after buying an additional 1,538 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Down 0.9%

IDXX stock opened at $670.46 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The company has a market capitalization of $53.54 billion, a PE ratio of 53.17, a price-to-earnings-growth ratio of 3.61 and a beta of 1.67. The company’s 50-day simple moving average is $705.35 and its 200 day simple moving average is $659.88. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the firm posted $2.80 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.98% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on IDXX shares. Barclays started coverage on IDEXX Laboratories in a research note on Monday, December 8th. They issued an “overweight” rating and a $850.00 price target on the stock. Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. BTIG Research upped their price target on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a report on Monday, November 3rd. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $763.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.